The Cefuroxime Application System is CIS Pharma’s patented drug/device combination for preparation and injection of cefuroxime intracameral antibiotic to prevent Endophthalmitis. It meets the cataract surgeon’s need to dilute and inject 1mg cefuroxime in a safe, precise and standardized manner.
Every year, 20 million cataract patients receive an intraocular lens. Endophthalmitis, also called intravitreal infection, is a rare but severe inflammatory condition of the eye, caused by microbial contamination during the surgical procedure. The incidence is reported between 0.1% and 0.05% without intracameral antibiotic prophylaxis. The treatment of Endophthalmitis is expensive and one out of two patients lose sight or the eye.
Cefuroxime intracameral prophylaxis was found to reduce the risk of Endophthalmitis by a factor 5, whereas topical antibiotics have no effect on the outcome. Intracameral cefuroxime prophylaxis has gained adoption in cataract clinics across the globe. In Europe intracameral cefuroxime is part of the cataract surgery guideline and is approved in most countries.